NIH Medical Safety Officer Reinstated

ByVera Sharav

NIH Medical Safety Officer Reinstated

Posted on: Friday, 23 December 2005, 15:00 CST

By JOHN SOLOMON

WASHINGTON – Reversing course, the government's premier health research agency has reinstated a medical safety expert who was fired after raising allegations of scientific misconduct and sexual harassment in federal AIDS research, his lawyer said Friday.

The National Institutes of Health's reinstatement of Dr. Jonathan Fishbein settles a two-year battle that prompted both congressional and federal investigations. It also drew attention to an entire class of researchers and safety experts the government initially claimed didn't deserve whistleblower protections.

Fishbein alleged he was fired for raising safety concerns in government AIDS research. NIH said he was fired for poor performance even though he had been recommended for a cash performance bonus just weeks before he was notified of his termination.

He was one of a few NIH whistleblowers whose plight was highlighted in Associated Press stories over the last year examining allegations of safety problems with federal AIDS research in the United States and Africa, sexual harassment of female NIH workers and the use of foster children to test AIDS drugs.

Fishbein was formally reinstated to a position of special assistant to the deputy director of NIH's National Institute of Allergy and Infectious Diseases, but he is unlikely to ever return directly to that office.

Fishbein is to look for a new assignment in government, but has been returned to the federal payroll, according to government officials

GA_googleFillSlotWithSize(“ca-pub-5440138744487553”, “News_Main_300x250”, 300, 250);

Fishbein's lawyer confirmed the rehiring.

"I can confirm that effective Dec. 12, 2005 that Jonathan Fishbein is reinstated and is now special assistant to the deputy director of NIAID," attorney Stephen Kohn said.

"The medical community owes a debt to Dr. Fishbein for his integrity and courageous efforts to ensure that humans are protected when they participate in drug trials," he said.

Numerous members of Congress, Republicans and Democrats alike, urged NIH not to fire Fishbein, saying he had raised important issues about the way patients are protected in government experiments.

Fishbein, an accomplished private sector safety expert, was hired by NIH in 2003 to improve the safety of its AIDS research.

He alleged that he was fired because he raised concerns about several studies and filed a formal complaint against one of the division's managers alleging sexual harassment of subordinates and a hostile workplace.

An administrative law judge originally ruled that Fishbein and hundreds of other doctors and medical safety experts like him had no whistleblower protections, like normal federal workers, because they were hired outside the civil service system as special employees at a higher salary.

The government subsequently reversed course and argued such workers should have some protections if they blow the whistle. NIH still proceeded to fire Fishbein.

An internal report to NIH chief Elias A. Zerhouni substantiated many of Fishbein's allegations, calling the agency's AIDS research division "a troubled organization" whose managers engaged in unnecessary feuding, sexually explicit language and other inappropriate conduct that hampered its global fight against the disease.

The review also concluded NIH's efforts to fire Fishbein gave the "appearance of reprisal." The report says no documentation was ever provided to Fishbein suggesting poor performance until after he complained about the safety in one sensitive AIDS study and filed a formal complaint alleging that the division's deputy director was acting unprofessionally with subordinates.

In addition, NIH's chief of AIDS research testified in a deposition this summer that the agency originally planned to transfer Fishbein to a different job in transplant and immunology research but decided instead to fire him when Fishbein filed an Equal Employment Opportunity Commission complaint

Fishbein's immediate supervisor "actually had a job for Dr. Fishbein lined up with DAIT (Division of Allergy, Immunology, and Transplantation) if he hadn't gone the route he had," Dr. Edmund Tramont testified.

"What do you mean, hadn't gone the route he had?," Fishbein's lawyer asked.

"When this all began, EEO complaints and all this other stuff, right? But we — you know, that got known. And so the directing potential to move into these other positions didn't happen," he said.

In its stories over the last year, AP reported:

-One of NIH's AIDS study in Africa violated federal safety regulations.

-Senior NIH managers engaged in sexually explicit pranks and sent expletive-laced e-mails to subordinates.

-NIH-funded researchers used foster children to test AIDS drugs since the late 1980s, many times not providing a basic protection afforded by federal law and required by some states. A subsequent federal investigation concluded at least one of the research institutions in those studies failed to comply with federal safety regulations.

Source: Associated Press/AP Online

More News in this Category

Related Articles

Similar Posts

  • AHRP Calls for Federal Investigation of Drug Trials Using Children in Foster Care

    RE: Phase I Drug trials used foster children in violation of 45 CFR 46.409 and 21 CFR 50.56

    The Alliance for Human Research Protection (AHRP) has reason to believe that federal regulations for the protection of children as research subjects have been seriously violated in federally funded HIV research.

    We have learned that a series of Phase I and Phase II drug experiments were conducted on infants and children who were under the guardianship of the New York City Agency for Children’s Services (ACS), and living at Incarnation Children’s Center, a foster care facility under contract with ACS.

  • Should the EPA Accept Human Pesticide Experiments?

    Testimony by Vera Hassner Sharav before the Committee on the Use of Third Party Toxicity Research with Human Research Participants; Science, Technology, and Law Program; The National Academies of Science Committee on the Use of Third Party Toxicity Research with Human Research Participants

    My name is Vera Sharav and I am the president and founder of The Alliance for Human Research Protection (AHRP) a citizens’ watchdog organization monitoring human research to ensure that the moral principles enshrined in the Nuremberg Code and the Declaration of Helsinki are preserved and followed in experiments involving human beings.

  • Best Pharmaceuticals for Children Act of 2002


    Comments submitted by The Alliance for Human Research Protection
    to The National Academy of Sciences
    Committee of the Institute of Medicine on Clinical Research Involving Children

    AHRP has been closely monitoring pediatric research trends since passage of the FDA Modernization Act of 1997. We believe that medications used in children should be thoroughly tested for safety, effectiveness and appropriate dose. But unlike adults who can exercise their autonomous right to informed consent, children who are enrolled in clinical trials are non-consensual human subjects. They should not, therefore, be made to assume the burden of testing possibly toxic drugs whose safety is unknown.

  • Protecting Human Subjects in Research: Are Current Safeguards Adequate?

    Current federal regulations set no limits on the level of risk that a competent adult may voluntarily choose to undertake for the sake of science. The regulations require prior approval by a review board (IRB) to ensure the research meets scientific and ethical justification, to ensure that the risks and benefits (if any) are fully disclosed to the subject, and that the subject can exercise the right to give or withhold informed consent.

  • FDA: Regulatory Protections for Children

    Comments submitted by Vera Hassner Sharav, John H. Noble, Jr., Ph.D and Howard Fishman, MEd, MSW for AHRP

    To: Dr. Bernard Schwetz Acting Commissioner Food and Drug Administration, Dockets Management Branch (HFA-305) Food and Drug Administration

    Re: COMMENT ON: Docket #00N-0074 April 24, 2001 Interim Rule: "Additional Safeguards for Children in Clinical Investigations of FDA-Regulated Products

    Excerpt: The FDA rightly chose not to permit the section 46.408 (c) waiver by IRBs of parental or guardian permission, as it leaves the specific circumstances for such a violation of parental rights to the discretion of local Institutional Review Boards (IRB). Given the stream of revelations of gross ethical and procedural violations at one after another of the nation’s premier research institutions, assumptions that “procedural safeguards are in place,” or that IRBs can be relied upon to make decisions that protect the best interests of human subjects – adults and children – has been debunked.